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Background: Acute kidney allograft rejection is a major cause for declining graft function and has a negative
impact on the long-term graft survival. The majority (90%) of acute rejections are T-cell mediated and, therefore, the
anti-rejection therapy targets T-cell-mediated mechanisms of the rejection process. However, there is increasing
evidence that intragraft B-cells are also important in the T-cell-mediated rejections. First, a significant proportion of
patients with acute T-cell-mediated rejection have B-cells present in the infiltrates. Second, the outcome of these
patients is inferior, which has been related to an inferior response to the conventional anti-rejection therapy. Third,
treatment of these patients with an anti-CD20 antibody (rituximab) improves the allograft outcome as reported in
single case observations and in one small study. Despite the promise of these observations, solid evidence is
required before incorporating this treatment option into a general treatment recommendation.
Methods/Design: The RIACT study is designed as a randomized, double-blind, placebo-controlled, parallel group
multicenter Phase III study. The study examines whether rituximab, in addition to the standard treatment with
steroid-boli, leads to an improved one-year kidney allograft function, compared to the standard treatment alone in
patients with acute T-cell mediated tubulointerstitial rejection and significant B-cell infiltrates in their biopsies. A
total of 180 patients will be recruited.
Discussion: It is important to clarify the relevance of anti-B cell targeting in T-cell mediated rejection and answer
the question whether this novel concept should be incorporated in the conventional anti-rejection therapy.
Trial registration: Clinical trials gov. number: NCT01117662
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High dose steroid therapy is standard-of-care for treating
acute T-cell mediated rejection of renal allografts, along
with intensified maintenance immunosuppressive ther-
apy in some cases (KDIGO-Guidelines [1]). Only a mi-
nority of patients (20%) appears to be non-responsive to
this treatment and may require additional treatments,
for example, anti-thymocyte globulins [2]. The general
perception is that successfully treated acute T-cell
mediated rejections do not harm the graft significantly.
Yet, in clinical experience not all patients will recover
with full function after the anti-rejection treatment. Par-
ticularly late rejections, occurring later than six months
after transplantation, may have detrimental effects on
long-term renal function [3,4]. Even if renal allograft
function returns to baseline values after anti-rejection
therapy this may reflect some degree of compensatory
hyperfiltration and obscure the loss of nephrons and de-
velopment of interstitial fibrosis and tubular atrophy (IF/
TA) [5]. In fact, several studies have established a rela-
tionship between progressive IF/TA and T-cell mediated
acute rejection even in subclinical rejection cases (that
is, without significant impairment of the glomerular fil-
tration rate at the time of rejection diagnosis) [6,7].
Given these facts, the current treatment of acute T-cell
mediated rejection may be suboptimal in many cases.
One possible explanation could be that this type of re-
jection is more complex than reflected by current
schemes and that therapy with steroids alone does not
fully address this complexity. Recent studies demon-
strated that more than 30% of the T-cell mediated tubu-
lointerstitial rejections additionally contain a significant
number of B-cells in the infiltrates [8]. The actual patho-
genetic role of these B-cell infiltrates remains to be
established but the first studies and our own data indi-
cate an inferior one-year allograft function and graft
survival in patients with T-cell mediated rejections with
B-cell infiltrates [9-11]. Steroid therapy alone, which is
primarily targeting T-cells, may not be adequate in these
cases, raising the question of additional B-cell directed
treatment strategies. Rituximab is a B-cell depleting anti-
body which is directed against the CD20 epitope and
leads to apoptosis of mature B cells. It has been
approved for treatment of diseases with B-cell activity,
such as B cell lymphoma and rheumatoid arthritis [12].
Thus far, only one pilot study examined the effect of
rituximab in the treatment of biopsy-proven acute T-cell
mediated rejection with B-cell infiltrates [13]. In this
randomized prospective study, 10 children with acute
T-cell mediated rejection with B-cell infiltrates were trea-
ted with rituximab in addition to standard-of-care anti-
rejection treatment (steroid boli and/or thymoglobuline).
Compared with the control group of 10 children who
received standard-of-care treatment only, rituximab-treated children had better recovery of allograft function
(P = 0.026) and improved biopsy rejection scores
(P <0.0001) at the follow-up biopsy after six months.
Furthermore, a few case reports in adults suggest a
benefit of rituximab alone or in combination with the
usual anti-rejection treatment in patients with acute
(therapy refractory) rejection [14,15].
Beneficial effects of targeting B cells in T-cell-
mediated acute rejection with rituximab can be based
on the concept that allospecific T-cell/B-cell cross-talk
in secondary lymphatic organs. After migration into the
allograft and into nodular/tertiary lymphatic organs, B-
cells induce an increased antigen presentation and
aggravated chemokine milieu [16]. This process may be
halted by rituximab, as a single dose of rituximab at
375 mg/m2 has been shown to induce a sustained re-
duction of B-cells in the peripheral blood but also in
the kidney allograft in most patients within the first 35
days [17].
Despite the promise of the cited studies [13,18] critical
evaluation invariably leads to the conclusion that the
evidence is not sufficient to treat acute transplant rejec-
tion with rituximab. This includes the small number of
reported cases, short follow-up periods and heterogen-
eity of inclusion criteria, and the histological grading in
these studies. Therefore, a double-blind, randomized,
placebo-controlled trial with a sufficient number of
patients and stringent histological defined inclusion cri-
teria is needed.
These aspects are considered in the design of the
RIACT-study. The acronym RIACT–study stands for a
multi-center randomized placebo controlled double
blind study to test the efficacy of RItuximab in Acute
Cellular tubulointerstitial rejection with B-cell infiltrates
in renal Transplant patients (RIACT).
Design
Study design
The RIACT-study is a randomized, double-blind, pla-
cebo-controlled, parallel group multicenter Phase III
study. The study hypothesis is that treatment with rituxi-
mab in addition to the standard therapy with steroid-
boli is superior to the standard therapy in acute T-cell
mediated tubulointerstitial rejections in which B-cell
infiltrates are present. The primary efficacy endpoint of
the study is the change of the glomerular filtration rate
(GFR) one year after intervention compared to the base-
line GFR before the rejection episode.
Secondary endpoints are: 1) the progression of intersti-
tial fibrosis and tubular atrophy (IF/TA) between the
allograft biopsy that led to enrollment in the study and a
scheduled protocol biopsy one year after intervention
and 2) safety and side effect aspects of rituximab in kid-
ney transplanted patients.
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acute T-cell mediated tubulointerstitial rejection who
also show significant B-cell infiltrates in their biopsies,
defined as >30 CD20+cells/hpf. After diagnosis of a B-
cell-rich acute T-cell mediated tubulointerstitial rejection
and informed consent (run-in phase), the patients will
be centrally randomized for double-blinded treatment
with rituximab or placebo, which will be given in
addition to the standard anti-rejection therapy with ster-
oid boli (study phase).
During the study phase a sufficient B-cell depletion
(<5 B-cells/μl peripheral blood) after the first application
of rituximab will be confirmed by fluorescence activated
cell sorting (FACS) analysis. Patients with rituximab
treatment and insufficient B-cell depletion undergo a
second intervention with the same dose of rituximab. If
a follow-up B-cell count in these patients reveals B-cells
numbers above the target value, these patients will be
excluded from the study. The follow-up period after
intervention is 12 months. At this time, the primary
endpoint renal allograft function change is determined,
along with the secondary endpoints as safety parameters
and degree of renal allograft fibrosis and tubular atrophy
in a protocol biopsy.Figure 1 Flowchart of the study design of the RIACT study. Independe
rejection therapy.The trial flow is outlined in Figure 1.
B-cell infiltrates in the biopsies are considered signifi-
cant in the RIACT study, when more than X400 are
found. However, the definition of significant B-cell infil-
trates is very heterogeneous in previously published
studies. The rationale for choosing 30 CD20+ cells /per
hpf (X400) in our trial is based on the observations of
our pilot study, which was also used for assessment of
graft outcome and sample size calculation. Furthermore,
the defined cell number lies within the limits reported in
other published studies [19].
Patients with Banff IA, IB or with a Banff borderline
rejection with a simultaneous increase in serum creatin-
ine of ≥20% over baseline values before the borderline
finding are eligible. The study will be carried out in Ger-
many by, so far, 13 leading kidney transplant centers.
The study design is illustrated in Figure 1.
For the study design we followed the guidelines “Euro-
pean legislation on orphan medicinal products (Regula-
tion (EC) No 141/2000)” and the “Guideline on Clinical
Trials in Small Populations (CHMP/EWP/83561/2005)”.
The study protocol has been approved by the local ethics
committees and national authorities. The trial is being
conducted in accordance with national laws, goodnt from the study protocol, all patients will receive steroid boli for
Table 1 Main inclusion and Exclusion criteria
Inclusion
criteria
1. Kidney transplantation >6 weeks and <12 months before
randomization
2. Age ≥18 years
3. Presence of an acute T-cell mediated tubulointerstitial
rejection (Banff IA or IB) or Banff borderline rejection with
simultaneous serum creatinine increase of ≥20% over
baseline
4. Significant numbers of B-cell infiltrates (defined as >30
CD20+cells /hpf)
5. Absence of C4d and SV40
6. Creatinine clearance >25 ml/min.
7. Reliable contraception
8. Written informed consent
Exclusion
criteria
1. Known adverse reactions against rituximab or concomitant
medication
2. Application of rituximab for any reason 12 months prior
inclusion
3. Women who are pregnant or breastfeeding
4. Active CMV, HIV, replicative Hepatitis B or C, or other
relevant infections
5. Splenectomy
6. Heart insufficiency (NYHA III-IV)
7. Severe arrhythmia
8. Insufficiently controlled diabetes mellitus (HbA1c >10 %)
9. Contraindication for a second transplant biopsy (for
example, coagulation disorders)
10. Other reasons according to the assessments of the study
physician
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Helsinki.
Inclusion and exclusion criteria
The population of renal allograft recipients is heteroge-
neous (for example, age, gender, first or repeated trans-
plant, immunological risk), yet, all patients are at risk for
acute rejection. Therefore, the inclusion criteria in the
RIACT–trial are laid down in a way that allows as many
patients as possible to participate in this study unless
medical reasons advise against inclusion. Included are all
female and male patients aged 18 years or older with the
diagnosis of a T-cell mediated acute tubulointerstitial re-
jection (Banff IA/IB, or borderline rejection with simul-
taneous increase of creatinine of ≥20% over baseline
creatinine before the borderline finding), and B-cell infil-
trates, defined as more than 30 CD20+cells/hpf. All im-
munosuppressive regimens according to local transplant
center standards at the time of rejection diagnosis are
acceptable, except previous use of rituximab to have the
obtained results applicable to a broad patient population.
Patients with a humoral rejection (morphological signs
of glomerulitis/capillaritis, positive C4d staining) and
patients with positive SV40 staining as a sign of
polyomavirus-infection are not eligible. The acute rejec-
tion must be diagnosed between 6 weeks and 12 months
after kidney transplantation. The baseline allograft cre-
atinine clearance (calculated by the abbreviated MDRD
formula [20]; before the rejection has to be over
25 ml/min. At screening, women of child-bearing age
must have a negative pregnancy test, must not be nurs-
ing and have to agree in using adequate contraception
throughout the study.
Patients are not eligible for the study entry if they had
previous adverse reactions against anti-CD20 antibodies,
have received rituximab within 12 months prior to the
planned inclusion in the RIACT study, have any active
infections (for example, active CMV, HIV or replicative
hepatitis B or C infection), or had a splenectomy. Rea-
sons for exclusion also include malignant tumors, car-
diac diseases, such as heart insufficiency (New York
Heart Association (NYHA) III-IV) or severe arrhythmia
(Table 1).
Sample size calculation
Sample size calculation is based on the t-test for inde-
pendent samples. It is assumed that ANCOVA with ad-
justment will lead to an increase of the power in the
final analyses. The type-I-error is set to 5% (two-sided)
and the power is set to 80%. The sample-size calculation
is based on the observations of 51 patients with acute T-
cell mediated tubulointerstitial rejection that were trea-
ted at the Medical School Hannover between 2007 and
2009. A total of 27 patients without B-cell infiltrationhad a mean increase over the baseline function before
the rejection in the GFR of 2.5 ml/min (± 24.5 standard
deviation) one year after treatment of the rejection epi-
sode. In the 24 patients with B-cell infiltrates, a deterior-
ation of GFR by minus 12 ml/min (± 27.8 standard
deviation) was observed.
A conservative assumption is that the change in GFR
over one year could be zero in the treatment group and
could be −12 ml/min in the control group, which would
require a sample size of 86 patients per group. In a more
optimistic scenario it is assumed that an improvement
of 2.5 ml/min can be achieved in the treatment group.
In the control group, the same deterioration as in
the conservative assumption (−12 ml/min) could be
observed. In this scenario, 58 patients per treatment
group would be necessary. Therefore, an interim analysis
is planned as soon as the primary endpoint is reached in
116 patients. An interim analysis plan according to
O’Brian and Flemming will be used [21]. The null hy-
pothesis is that the change of the GFR is the same in
patients treated with rituximab and under placebo. The
null hypothesis is rejected in the interim analysis if the
one-sided P-value is less than 0.005. In case the study is
Schiffer et al. Trials 2012, 13:199 Page 5 of 8
http://www.trialsjournal.com/content/13/1/199continued to the final analysis, the null hypothesis can
be rejected if the P-value in the final analysis is less than
0.023 (one-sided). The application of this interim ana-
lysis increases the number of patients per treatment arm
to 88 patients.
If the optimistic assumption for the sample size calcu-
lation holds true, the study has a chance of approxi-
mately 60% to reject the null hypothesis at the time of
the interim analysis and thus ended at this point. In
addition, the study could be terminated, with consult-
ancy of the data monitoring committee, due to expected
inefficacy.
Although all efforts will be done to achieve complete
data for the primary endpoint for all patients, two add-
itional patients will be recruited per treatment group to
ascertain sufficient numbers of patients in each group.
Thus, a total of 180 patients will be included into the
trial. A recruitment period of three years is expected
with 13 centers recruiting for the trial.
Interventions and study plan
The diagnosis of an acute T-cell mediated tubulointersti-
tial rejection (Banff IA/IB) or a Banff borderline rejec-
tion with significant numbers of B-cells in the infiltrates
is one of the major inclusion criteria for the RIACT
study. To ensure a timely beginning of the anti-rejection
therapy, the histopathological diagnosis will be made by
the pathologists who are usually consulted by each par-
ticipating center for kidney biopsy evaluation (all pathol-
ogists are in university departments). To achieve the
highest degree of comparability and to reduce inter-
center variability in the histopathological diagnosis, all
pathologists will be provided with the same automated
immunohistochemical staining platform (BondMaxTM,
A. Menarini Diagnostics, Berlin, Germany). The stain-
ings will be performed using the same stainer program
and the same antibody- and staining-solutions. For the
screening, the biopsies will be stained for CD20, C4d
and SV40 in the above described fashion, in addition to
the normal chemical stainings performed in each center
for the rejection diagnosis.
All patients that fulfill the medical inclusion criteria
and the histological inclusion criteria are asked to par-
ticipate in the RIACT-study. After obtaining their writ-
ten informed consent, patients attend a screening visit.
At this visit the patients are asked to provide a medical
history (with emphasis on the transplant history) and
undergo a physical examination. Vital signs are mea-
sured and blood samples are taken to determine creatin-
ine, cystatin C, electrolytes, liver enzymes and blood
counts, including B-cell count by FACS-analysis. Fur-
thermore, a urine status will be assessed (leukocytes, ni-
trite, protein, haemoglobin). To exclude pregnancy at
the time of inclusion, ß-HCG-levels in female patientsare measured. According to the standard therapy proto-
col for acute T-cell mediated tubulointerstitial rejection,
all patients will receive the first, out of three, steroid
bolus upon detection of B-cell infiltrates in the biopsy
(defined as more than 30 CD20+-cells/hpf ), patients
enter the double-blind treatment period by
randomization to treatment with either (A) standard
treatment (two more steroid boli for the next two days)
plus placebo (500 ml NaCl0,9%), or (B) standard treat-
ment (steroid boli for the next two days) and the study
drug, a single dose intravenous infusion of rituximab
(375 mg/m2).
Both treatment groups will receive additional medica-
tion that is intended to prevent potential side effects of
rituximab, consisting of antihistaminics and an antipyr-
etic medication (paracetamol) together with the study
medication. All patients will also receive prophylaxis for
pneumocystis jirovecii pneumonia for six months after
the anti-rejection treatment according to the local center
schemes.
According to the literature, a single dose of rituximab
at 375 mg/m2 is able to induce a sustained reduction of
B-cells in the peripheral blood but also in the renal allo-
graft in most patients within the first six weeks [17]. Fol-
lowing these findings and with the aim to keep the
dosage of rituximab and, therefore, possible side effects
as low as possible, rituximab will be given generally only
once in the RIACT study. To assure a complete B-cell
depletion in the peripheral blood (defined as <5 B-cells/
μl), B-cell numbers in the peripheral blood will be
assessed by FACS analysis on Day 35 ± 7.
Patients in the rituximab group with more than five B-
cells/μl on Day 35 ± 7 will receive a second dose of
rituximab (375 mg /m2). Accordingly, sufficient numbers
of patients in the placebo group will be randomized in
advance to receive a second round of placebo treatment.
(For each patient in the placebo group it will be rando-
mized in advance whether he will receive a second
round of placebo treatment or not. If the rate of patients
that need a second dose of rituximab is lower or higher
than expected, the rate of patients that receive a second
dose of placebo will be adapted.) In patients with a sec-
ond treatment course, B-cells counts will be repeated on
Day 72 ± 7. Patients in the verum group that continue
to have more than five B-cells/μl in the peripheral blood
will not receive further treatments with rituximab.
Nevertheless, these non-responders will be followed at
the regular study visits as well.
At the half-year visit after randomization (Day 182 ±
28), B-cell counts and laboratory tests will be repeated
in all patients. One year after enrollment (Day 365 ± 28),
final hematological and laboratory tests and a re-biopsy
of the transplant will be performed (see Table 2). The
progression of interstitial fibrosis and tubular atrophy
Table 2 Study visits






-assessment of allograft function
-beginning of rejection therapy (steroids) according
to center standards
-randomization
Visit 2 (Day 0) -rituximab or placebo + standard concomitant
medication
Visit 3 (Day 1) - physical examination
- patient history for specific side effects
Visit 4








second application of study medication or placebo
(Visit 4a))





- patient history for specific side effects












- assessment of allograft function
Visit 6




- assessment of allograft function
- re-biopsy
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study and the biopsy one year after intervention will be
quantified using specific staining und computerized
image analysis.
Methods against bias
The RIACT study is a double-blind, randomized,
placebo-controlled phase III trial. Randomization will be
performed centrally stratified by study center. The allo-
cation to treatment arms results from a permuted-block
randomization with variable block length. FACS results,
that could give a hint which patient is in the verum re-
spectively in the placebo group, will not be handed out
to the study physician, but will be sent from the FACS
facility to the unblinded randomization team in theDepartment of Biostatistics. The study physician will get
the information concerning which patient has to receive
a second dose of medication from the randomization
team.
The biopsy readings, including quantification of fibro-
sis, will be done without knowledge of the assignment to
the treatment groups. All biopsies will be submitted to a
second reading by a panel of renal pathologists. Biopsies
with divergent diagnoses will be discussed by the path-
ology consortium to reach a final diagnosis.
The primary analyses will be conducted on the
intention-to-treat (ITT) population. Patients without
complete B-cell depletion will also be observed and
assessed according to the study protocol.
The likelihood of drop-outs from the study is negli-
gible as all patients are under continuous surveillance in
the participating centers. Although some patients may
wish to withdraw prematurely from the trial, it is
assumed that GFR-values one year after inclusion into
the study - the primary endpoint of the study - can be
obtained from all patients. However, if the GFR one year
after inclusion into the study cannot be assessed, the last
known plausible GFR value will be used, because it is
assumed that a critical clinical progress will be carefully
monitored.Study assessments
The GFR of the renal allograft is the ultimate parameter
that describes acute and chronic aspects of the graft
function and is the most widely used measure for the
outcome in renal transplantation studies. Sensitivity of
the GFR can be improved by using the patients’ individ-
ual percentage change in GFR in a defined time interval
(“delta GFR”). The primary objective is to show that
additional anti-rejection treatment with rituximab is
more efficacious than the standard anti-rejection treat-
ment with regard to the allograft function one year after
these treatments. For this purpose, individual changes in
the glomerular filtration rate (GFR) will be determined
using the baseline GFR before the rejection and the
value at one year after rejection treatments. The GFR
will be calculated using the simplified MDRD formula
(eGFR = 186*(0.742 for females)*creatinine-1.153*age
−0.203) [20].
As a second endpoint, interstitial fibrosis and tubular
atrophy (IF/TA) will be used as an indicator of estab-
lished chronic damage. To achieve maximum possible
accuracy, biopsy specimens will be stained for fibrosis
(Sirius Red) and quantified by computerized image ana-
lysis in specified areas of the renal tissue (renal cortex).
Again, to enhance the informational value of this par-
ameter, the patient’s individual change of IF/TA in the
initial biopsy at the time of acute rejection and inclusion
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used (“delta-IF/TA”).
To assess the safety of the intervention, occurrence
and frequency of adverse events in both treatment
groups will be analyzed. These include the patient’s self-
reported events and those inquired about by the study
physician during regular study visits or obtained from
additional in- and outpatient attendances. As a com-
bined secondary safety endpoint, further rejection epi-
sodes, terminal graft failure during the observation
period, severe infections and patient deaths will be
analyzed.
Ethics statement
The study was approved by the ethics committee of
Hannover Medical School as the leading center and the
Paul Ehrlich Institute, as well as by all local ethics com-
mittees of the participating centers.
Statistical analysis
The primary analyses will be performed in all patients
who have received a least one dose of the study medica-
tion. Sensitivity analyses will be performed in the per
protocol population, including all patients that finish the
study at the last visit one year after study entry. The
change in GFR between baseline and the assessment one
year after the rejection episode will be performed with
ANCOVA analysis adjusted for baseline, treatment and
center. One interim analysis and one final analysis will
be performed in this trial following the aforementioned
decision rules (see Sample size calculation).
As soon as it can be demonstrated that rituximab is
superior to placebo with respect to the primary end-
point, the secondary endpoint progression of interstitial
fibrosis and tubular atrophy will be assessed in a con-
firmatory sense. Increase of fibrotic and atrophic inter-
stitial area is analyzed with ANCOVA with treatment,
center and baseline IF/TA in the first biopsy included
as co-variates. Subanalyses will include the effect of
rituximab in patients with different severity grades of
rejection (Borderline, Type I and II), different immuno-
supression before inclusion in the study and patient
groups receiving one versus two applications of rituxi-
mab. Frequency of adverse events will be reported per
treatment group and analyzed with a chi-square test.
P-values will be assessed descriptively.
Discussion
Acute T-cell mediated tubulointerstitial rejections occur
in 15 to 30% of all transplanted patients. In approxi-
mately 30% of these cases, B-cell infiltrates are detect-
able, which may be associated with less beneficial
transplant outcomes. However, the current standard
therapy for acute rejections focuses on T-cells.The RIACT study, therefore, tests the hypothesis that
additional treatment of the rejection with rituximab is
more efficacious than the standard treatment with ster-
oid boli alone. This novel therapy will be studied in a
multi-center randomized, placebo controlled, double
blind trial with a sufficient number of patients. The re-
cruitment of 180 eligible patients will be challenging
despite the multi-centric approach with 13 participating
centers. Should the recruitment rate prove to be lower
than expected in the first six months after the study
begins, more centers will be asked to participate. If this
study proves that rituximab is beneficial in acute rejec-
tions that contain B-cell infiltrates with regard to the
long-term allograft function and without a significant in-
crease in adverse events, future protocols for the treat-
ment of acute rejection most likely will have to
incorporate the concept of B-cell targeting.
Trial status
The study is recruiting patients.
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